Phase II trial of weekly paclitaxel (80 mg/m 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

To evaluate the activity of single agent weekly paclitaxel in patients with both platinum and paclitaxel (delivered every 3 weeks)-resistant ovarian cancer. Forty-eight patients with platinum and paclitaxel-resistant ovarian cancer (defined as progression during, or recurrence

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2006-06, Vol.101 (3), p.436-440
Main Authors: Markman, Maurie, Blessing, John, Rubin, Stephen C., Connor, Joseph, Hanjani, Parviz, Waggoner, Steven
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - adverse effects
Chemotherapy of ovarian cancer
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Humans
Middle Aged
Organoplatinum Compounds - pharmacology
Ovarian cancer
Ovarian Neoplasms - drug therapy
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Paclitaxel-resistant ovarian cancer
Peritoneal Neoplasms - drug therapy
Platinum-resistant ovarian cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the activity of single agent weekly paclitaxel in patients with both platinum and paclitaxel (delivered every 3 weeks)-resistant ovarian cancer. Forty-eight patients with platinum and paclitaxel-resistant ovarian cancer (defined as progression during, or recurrence
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2005.10.036